Analytical Data
-
基因名
VSIG4
-
简介
VSIG4 Protein, a phagocytic receptor, robustly inhibits T-cell proliferation and IL2 production, serving as a potent alternative complement pathway convertase inhibitor. VSIG4 Protein, Human (HEK293, His) is the recombinant human-derived VSIG4 protein, expressed by HEK293 , with C-6*His labeled tag.
- Application
-
别名
V-Set and Immunoglobulin Domain-Containing Protein 4; Protein Z39Ig; VSIG4; CRIg; Z39IG
-
种属
Human
-
表达系统
HEK293
-
标签
C-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9Y279-1
-
表达区间
R20-P283
-
氨基酸序列
RPILEVPESVTGPWKGDVNLPCTYDPLQGYTQVLVKWLVQRGSDPVTIFLRDSSGDHIQQAKYQGRLHVSHKVPGDVSLQLSTLEMDDRSHYTCEVTWQTPDGNQVVRDKITELRVQKLSVSKPTVTTGSGYGFTVPQGMRISLQCQARGSPPISYIWYKQQTNNQEPIKVATLSTLLFKPAVIADSGSYFCTAKGQVGSEQHSDIVKFVVKDSSKLLKTKTEAPTTMTYPLKATSTVKQSWDWTTDMDGYLGETSAGPGKSLP
-
蛋白长度
Extracellular Domain
-
分子量
40.0 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
VSIG4 (V-set and immunoglobulin domain-containing protein 4) is a recently identified immune checkpoint molecule that plays a critical role in regulating immune responses. It is predominantly expressed on the surface of immune cells, particularly dendritic cells and macrophages, where it interacts with specific receptors on T cells to inhibit their activation. This mechanism of action positions VSIG4 as a potential target in therapeutic strategies aimed at modulating immune responses in various diseases, including cancer, autoimmune disorders, and transplant rejection. Its engagement in immune regulation underscores its significance in maintaining immune homeostasis and preventing excessive inflammation. Recent studies have begun to explore the structural and functional characteristics of VSIG4, revealing its potential as a promising biomarker for immune-related diseases and a novel target for immunotherapy. Furthermore, understanding the pathways involved in VSIG4-mediated immune regulation could lead to the development of innovative treatments that enhance antitumor immunity or restore tolerance in autoimmune conditions. As research progresses, targeting VSIG4 may provide new avenues for therapeutic intervention, making it an important focus within the field of immunology and molecular medicine.
